Russian Nanotechnologies Corp. plans to work with Domain Associates, a U.S. venture fund, to invest $760 million in U.S. life science companies and build facilities in Russia.
Rusnano, as the state-owned company is known, and Domain will invest in about 20 U.S.-based health-care technology companies involved in pharmaceuticals, biotechnology and medical devices, the Moscow-based company said today in an e-mailed statement. The partners plan to bring in co-investors, according to the statement.
To contact the reporter on this story: Jason Corcoran in Moscow at email@example.com
To contact the editor responsible for this story: Frank Connelly at firstname.lastname@example.org